BerGenBio ASA BGBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BGBIO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- NOK 0.14
- Day Range
- NOK 0.14–0.15
- 52-Week Range
- NOK 0.08–0.52
- Bid/Ask
- NOK 0.15 / NOK 0.15
- Market Cap
- NOK 566.76 Mil
- Volume/Avg
- 14.8 Mil / 43.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 294.82
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 18
- Website
- https://www.bergenbio.com
Valuation
|
Metric
|
BGBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.32 |
Price/Sales | 294.82 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BGBIO
|
|---|---|
Quick Ratio | 6.33 |
Current Ratio | 7.01 |
Interest Coverage | −147.82 |
Quick Ratio
BGBIO
Profitability
|
Metric
|
BGBIO
|
|---|---|
Return on Assets (Normalized) | −123.35% |
Return on Equity (Normalized) | −182.03% |
Return on Invested Capital (Normalized) | −179.99% |
Return on Assets
BGBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rbxccwswy | Czlrz | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Plwvphyhg | Lxzvl | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gsqrltlc | Rtjtyq | $103.7 Bil | |
MRNA
| Moderna Inc | Mwwfrvbwg | Qcysj | $47.9 Bil | |
ARGX
| argenx SE ADR | Trkfjwbf | Dbkp | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Ydyggch | Tlpyr | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hjnbfhtw | Tmkcyx | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Myflqgwgb | Cmwjypq | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kgfyyzfw | Jhpvt | $12.8 Bil | |
INCY
| Incyte Corp | Cshyxxnw | Wtbpw | $12.1 Bil |